Now more than ever we should be working together on uniquely American solutions to save lives, lower cost, and uphold the dignity and right of every person to live a full life.

The Congressional Budget Office confirmed that there will be fewer new medicines as a result of government price controls that ultimately passed the House.

Let's reject price controls and focus on bipartisan work like solutions in H.R. 19, which will result in increased competition and lower patient cost without sacrificing the future of biomedical innovation in the United States.

The story of American biomedical innovation is one that should be celebrated.

Price controls, price controls that are being included right now in President Biden's plan will kill innovation and lurch us more toward government-controlled healthcare.

It is a false choice on families like Crystal Davis who believed in the promise of America so that her son with SMA can live a full life.

I am concerned that that foundation is in jeopardy and potentially being dismantled by the proposed government price controls.

Surely, we all agree that less innovation, fewer cures, and a dependency on China cannot be America's future.

I do not believe it. It is a false choice.

Fentanyl and fentanyl-related substances are killing a record number of Americans. Making sure that these deadly poisons are permanently made illegal requires urgent action.

According to CDC's National Center for Health Statistics, there were over 100,000 drug overdoses in the United States from April 2020 to 2021.

It is time that we did our part to permanently make these fentanyl-related substances illegal and Schedule I.

We need to take urgent action on fentanyl analogs. It is too deadly a substance to be weak on traffickers.

Congress needs to make permanent the fentanyl analogs ban immediately, along with existing criminal penalties.

We wouldn't have to be talking about those things if there was no fentanyl in the system in the first place.

This Administration must be serious about making decisions within the statutory deadlines for new chemicals.

Failing to provide industry the confidence they and downstream customers need regarding options to improve their products and compete globally in a timely matter manner is a significant shortcoming.

Thank you, Mr. Chairman. Happy birthday, Mr. Chairman.

So, bottom line, we want to make sure that we are fulfilling the statutory deadline. That needs to be the goal, no matter who is in the White House.

This authority should be used, but with care, prudence, and predictability.

I hope that the Biden Administration will learn a lesson from these mandates that have made Washington State a difficult place right now.

Overall, states regulate the practice of medicine. At the Federal level, we need to support states and share best practices.

While I support the intent of this program, this is the wrong way to legislate.

The hard-working men and women of this country, especially our frontline healthcare workers, our heroes, need solutions, not force and fear that is eroding trust in public health.

Your sacrifices, especially during these most uncertain times, is why we will not stop our investigation into COVID-19 origins.